Haloperidol has mixed effects in ICU patients with delirium

Abstract

Haloperidol was not significantly more effective than placebo in leading to more days alive and out of the hospital among intensive care patients with delirium, a randomized trial has found. The trial did, however, show a lower 90‐day mortality rate among patients receiving haloperidol, a finding that was not a primary outcome in the study. Results were published Dec. 29, 2022, in the New England Journal of Medicine.